1.1. masitinib mesylate -Orphan - H0005118
AB Science, in combination with riluzole is indicated for the treatment of adult patients with
amyotrophic lateral sclerosis (ALS)
Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated
Action: For adoption
The CHMP did not agree to the request for accelerated assessment and adopted the briefing
note and Rapporteurs' recommendation on the Request for Accelerated Assessment.